HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy
NCT ID: NCT07312045
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
180 participants
OBSERVATIONAL
2025-11-25
2026-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III/IV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit.
The primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gingivitis Patients
Participants with visible signs of gingival inflammation and bleeding on probing, but without clinical attachment loss or radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy.
Non-surgical Periodontal Therapy
Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.
Stage III/IV Periodontitis Patients
Participants diagnosed with stage III or stage IV periodontitis, characterized by clinical attachment loss, probing depth ≥5 mm, and radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy and will be re-evaluated at 3 months.
Non-surgical Periodontal Therapy
Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.
Periodontally Healthy Individuals
Participants with no clinical signs of gingival inflammation, probing depth ≤3 mm, no clinical attachment loss, and no radiographic bone loss. These individuals serve as the healthy control group.
Non-surgical Periodontal Therapy
Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-surgical Periodontal Therapy
Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide informed consent
* No systemic diseases or conditions affecting periodontal status
* For Healthy Group: Probing depth ≤3 mm, no attachment loss, no radiographic bone loss
* For Gingivitis Group: Gingival inflammation and bleeding on probing without attachment loss or bone loss
* For Periodontitis Group: Stage III or stage IV periodontitis according to 2018 classification
* No periodontal treatment within the past 6 months
* Willingness to attend follow-up visits
Exclusion Criteria
* Current pregnancy or lactation
* Use of antibiotics, anti-inflammatory medications, or immunosuppressive drugs within the last 3 months
* Smokers or individuals using tobacco products
* History of periodontal surgery in the last 6 months
* Presence of fewer than 20 natural teeth
* Any condition that may interfere with study participation or data reliability
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ömer Faruk Okumuş
OTHER
Erzincan Binali Yildirim Universitesi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ömer Faruk Okumuş
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erzincan Binali Yıldırım University Faculty of Dentistry
Merkez, Erzincan, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ömer Faruk Okumuş, Assistant Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBYU-HALP-2025
Identifier Type: -
Identifier Source: org_study_id